FILSUVEZ® (Birch Triterpene Gel)
- Indication
- Treatment of partial-thickness wounds associated with Epidermolysis Bullosa (EB) in patients aged 6 months and older
- Manufacturer
- Chiesi Group (凯西集团)
- Lecheng Status
- First patient treated + real-world study launched (June 2026) at Boao Future Hospital
- Available At
- 海南省妇女儿童医学中心乐城分院（博鳌未来医院）
- Regulatory Status
- FDA: Approved (December 2023); EMA: Approved (June 2022); NMPA: Not yet approved (accessible via Lecheng special access + real-world study)
Common Questions
Who is eligible for this treatment?
Patients with confirmed indication and a treating physician referral. International patients need a medical visa (M visa).
How can I access this treatment in Lecheng?
Contact the hospital listed in the quick facts section. International patients can use medical agents or contact the hospital directly.
What is the cost of treatment?
Costs vary by treatment protocol and length of stay. Please contact the hospital for accurate pricing. International insurance may be accepted.
Indication: Treatment of partial-thickness wounds associated with Epidermolysis Bullosa (EB) in patients aged 6 months and older
Manufacturer: Chiesi Group (凯西集团)
The world's first and only approved treatment for Epidermolysis Bullosa (EB), a rare genetic disease causing extremely fragile skin ('Butterfly Children'). Global Phase III trial showed 44% improvement in wound closure within 45 days and 6.8 days faster healing compared to control. FDA and EMA approved with Orphan Drug designation. China has ~15,000 EB patients. FILSUVEZ® is currently the ONLY accessible EB treatment in China via Lecheng special access policy.
Sources & Citations
- hainanlecheng.com · accessed 2026-07-03